PV Bulletin

Update on PRAC Outcomes Affecting Injectable Iron Medicines

The recent PRAC meeting has led to new recommendations on the monitoring of injectable iron medicines, specifically regarding the risk of hypophosphatemia.

Primary source: Retour d'information sur le PRAC de septembre 2025 (1 - 4 septembre)

Translated from French

PV Bulletin does not take any responsibility for translation errors or omissions, though it has used the best available translation engine.

Add to My Intelligence

Sign in with your work email to save this update, triage it, and track follow-up.

Sign in to save

PV Impact Brief

Awareness · MediumConfidence: low

What changed

New guidance emphasizes enhanced monitoring for injectable iron medications, specifically focusing on the risk of hypophosphatemia and associated bone issues. It is required that healthcare professionals monitor blood phosphate levels in patients at risk, particularly those receiving high doses or long-term treatment.

Why it matters

These updates from the PRAC will have a significant impact on patient safety and risk management strategies for injectable iron medications, mandating stricter monitoring to mitigate potential risks.

Action needed

Sign in to unlock the full action card and owner assignment.

Sign in with your work email to read the full operational brief, action card, and evidence ledger.

Continue reading with PV Bulletin

Sign in with your work email to unlock the full briefing, regulatory action card, evidence ledger, and role-specific next steps.

Related updates for your role

publicEuropean Medicines Agency · European Union · Updated Sep 24, 2026

New Guidance on Coordinating Good Clinical Practice Inspections in the EU

Awareness · Medium

PV teams should update their workflows regarding inspection readiness, review standard operating procedures (SOPs) to align with the new GCP inspection coordination processes, and ensure that all relevant personnel are trained on the updated guidance.

Inspection ReadinessPV Quality Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: PV Quality Lead, Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicEuropean Medicines Agency (EMA) · European Union · Updated Sep 25, 2026

Guidance on Real-World Data Collection for Regulatory Decisions

Awareness · Medium

PV teams should review and update their Standard Operating Procedures (SOPs) related to real-world data collection methodologies and ensure alignment with the new guidance emerging from the workshop. Training may also be required to enhance understanding of RWD's impact on regulatory submissions.

Signal ManagementRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicEuropean Medicines Agency · European Union · Updated Sep 24, 2026

New Clinical Guidelines for Thalassaemia Drug Development

Awareness · Medium

PV teams should update their regulatory intelligence monitoring workflows to include the timelines and requirements established by the EMA for thalassaemia treatments. It's essential to ensure adherence to the new guidelines in clinical trial designs.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicEMA · European Union · Updated Sep 24, 2026

New Clinical Guidelines for Sickle Cell Disease Therapeutics

Awareness · Medium

Update workflows related to regulatory intelligence monitoring and ensure that all relevant SOPs reflect the new guidelines on clinical requirements for sickle cell disease treatments.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward